2023 - Research.com Medicine in Netherlands Leader Award
His scientific interests lie mostly in Internal medicine, Heart failure, Cardiology, Ejection fraction and Heart disease. His Internal medicine research integrates issues from Placebo and Endocrinology. Dirk J. van Veldhuisen has included themes like Randomized controlled trial, Surgery, Anemia, Intensive care medicine and Hazard ratio in his Heart failure study.
The concepts of his Ejection fraction study are interwoven with issues in Carvedilol, Beta blocker, Clinical endpoint and Breast cancer. Dirk J. van Veldhuisen interconnects Pregnancy, Sudden death and Randomization in the investigation of issues within Heart disease. His research integrates issues of Eplerenone, Spironolactone, Brain natriuretic peptide and Coronary artery disease in his study of Myocardial infarction.
Dirk J. van Veldhuisen mostly deals with Internal medicine, Heart failure, Cardiology, Ejection fraction and Myocardial infarction. His Internal medicine study which covers Endocrinology that intersects with Gastroenterology. His Heart failure research includes themes of Randomized controlled trial, Surgery, Intensive care medicine and Hazard ratio.
His Cardiology study combines topics from a wide range of disciplines, such as Placebo and Heart rate. His biological study spans a wide range of topics, including Eplerenone, Clinical endpoint, Blood pressure and Cohort. The various areas that he examines in his Renal function study include Creatinine and Kidney.
His main research concerns Internal medicine, Heart failure, Cardiology, Ejection fraction and Atrial fibrillation. Borrowing concepts from In patient, Dirk J. van Veldhuisen weaves in ideas under Internal medicine. His Heart failure research is multidisciplinary, relying on both Gastroenterology, Hazard ratio, Confidence interval and Renal function.
He studied Cardiology and Stroke that intersect with Rivaroxaban. His work is dedicated to discovering how Ejection fraction, Beta blocker are connected with ACE inhibitor and other disciplines. Dirk J. van Veldhuisen works mostly in the field of Atrial fibrillation, limiting it down to topics relating to Risk factor and, in certain cases, Quality of life, as a part of the same area of interest.
Dirk J. van Veldhuisen mainly investigates Internal medicine, Heart failure, Cardiology, Ejection fraction and Hazard ratio. His Internal medicine study frequently draws connections between adjacent fields such as Gastroenterology. His research in Heart failure intersects with topics in Confidence interval, Proportional hazards model, ACE inhibitor, Biomarker and Cohort.
His Cardiology research incorporates themes from Clinical trial and Angiotensin receptor. His Ejection fraction research includes elements of Cohort study, Diabetes mellitus, Magnetic resonance imaging, Fibrosis and Hyperkalemia. His work carried out in the field of Hazard ratio brings together such families of science as Renal function, Urology, Loop diuretic, Diuretic and Volume overload.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).
Kenneth Dickstein;Alain Cohen-Solal;Gerasimos Filippatos;John J V McMurray.
European Journal of Heart Failure (2008)
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
Faiez Zannad;John J. V. McMurray;Henry Krum;Dirk J. van Veldhuisen.
The New England Journal of Medicine (2011)
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).
Silvia G. Priori;Carina Blomström-Lundqvist.
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)
Marcus D. Flather;Marcelo C. Shibata;Andrew J.S. Coats;Dirk J. Van Veldhuisen.
European Heart Journal (2005)
Rosuvastatin in Older Patients with Systolic Heart Failure
John Kjekshus;Eduard Apetrei;Vivencio Barrios;Michael Böhm.
The New England Journal of Medicine (2007)
Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population
Hans L. Hillege;Vaclav Fidler;Gilles F.H. Diercks;Wiek H. van Gilst.
Renal function, neurohormonal activation, and survival in patients with chronic heart failure
Hans L. Hillege;Armand R. J. Girbes;Pieter J. de Kam;Frans Boomsma.
Targeted Anticytokine Therapy in Patients with Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)
Douglas L. Mann;John J.V. McMurray;Milton Packer;Karl Swedberg.
Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis
Joost P van Melle;Peter de Jonge;Titia A Spijkerman;Jan G P Tijssen.
Psychosomatic Medicine (2004)
Lenient versus strict rate control in patients with atrial fibrillation.
Isabelle C. Van Gelder;Hessel F. Groenveld;Ype S. Tuininga;A. Marco Alings.
The New England Journal of Medicine (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: